CYTK.NASDAQCytokinetics INC

Form 4: Cytokinetics CEO Sells Shares

Sentiment:

Insider Transaction (Form 4)


Robert I Blum, President & CEO and a Director of Cytokinetics Inc, sold 7,500 shares of common stock on July 13, 2026 for $82.02 per share.

Summary

  • Open-market sale: disposed of 10 Common Stock at $82.02 ($820) on July 13, 2026; holds 377,820 after (Direct).
  • Option exercise/conversion: acquired 7,490 Common Stock at $10.60 ($79,394) on July 13, 2026; holds 385,310 after (Direct).
  • Open-market sale: disposed of 7,490 Common Stock at $82.02 ($614,330) on July 13, 2026; holds 377,820 after (Direct).
  • Option exercise/conversion: disposed of 7,490 Non-Qualified Stock Option (Right to Buy) on July 13, 2026; holds 186,745 after (Direct).

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $615,150 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.

Insider Transactions

Robert I Blum — Director, Officer (President & CEO)

Transaction made under a Rule 10b5-1 trading plan.

DateTransactionSecuritySharesPriceValueHeld After
2026-07-13Open-market saleCommon Stock10$82$820377,820
2026-07-13Option exercise/conversionCommon Stock7,490$11$79.4K385,310
2026-07-13Open-market saleCommon Stock7,490$82$614.3K377,820
2026-07-13Option exercise/conversionNon-Qualified Stock Option (Right to Buy)7,490——186,745

Key Dates

DateDescription
2026-07-13Open-market sale (10 shares)
2026-07-13Option exercise/conversion (7,490 shares)
2026-07-13Open-market sale (7,490 shares)
2026-07-13Option exercise/conversion (7,490 shares)

Keywords

insider transaction, Form 4, CYTK, CYTOKINETICS INC, bearish, Robert I Blum

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.